MNKD - MannKind Corporation
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that Chief Executive Officer Michael Castagna will participate in a panel focused on innovation across chronic respiratory diseases at the Chardan Healthcare Conference. Management will also participate in one-on-one meetings with investors during the conference.
New analyses on Furoscix ReadyFlow PK/PD performance delivered via an autoinjector demonstrated comparable urine output to IV furosemide Consistent bioavailability, diuresis and natriuresis across injection sites support flexible administration in clinical practice Cross-study analysis demonstrates comparable diuretic and natriuretic responses between Furoscix ReadyFlow and Furoscix (furosemide) On-body Infusor, supporting a seamless transition to ReadyFlow Data presentations build on the July 2026 FDA approval and U.
MannKind NASDAQ: MNKD CFO Chris Prentiss outlined the company's commercial and development priorities at the H.C. Wainwright Global Investment Conference, emphasizing execution following three major 2026 catalysts: expanded pediatric approval for Afrezza, the launch of FUROSCIX ReadyFlow, and Phase 1b data for MNKD-201 in idiopathic pulmonary fibrosis, or IPF.
MannKind Corporation (NASDAQ:MNKD) shares are trading lower on Wednesday as traders react to the company's entry into a licensing and collaboration deal tied to an inhaled, rapid-acting GLP-1 program.
Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere ® inhalation technology MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
UTHR's ralinepag NDA receives FDA acceptance, with a 2027 decision ahead as positive phase III data support its PAH potential.
Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity should be adequate to fund its operations and launches for ~2.3 years.
MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript
MannKind NASDAQ: MNKD reported second-quarter revenue of $109.4 million, up 43% from the prior-year period, as growth in its commercial products and collaboration revenue helped offset increased spending tied to product launches and development programs.
The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
MannKind (MNKD) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to break-even earnings per share a year ago.
Achieved three major catalysts to drive future growth: Launched the pediatric indication of Afrezza ® following FDA approval FUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and CKD Positive nintedanib DPI Phase 1b data in IPF patients validates continued Phase 2 advancement Encouraging early momentum in Afrezza pediatric launch 1 in 3 of the top 100 pediatric insulin writers have prescribed Q2 2026 total revenues of $109.4M, +43% vs. Q2 2025 Conference call and webcast today at 4:30 p.m.
MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript
MannKind NASDAQ: MNKD reported Phase 1b results for its inhaled nintedanib dry-powder inhalation, or DPI, candidate in patients with idiopathic pulmonary fibrosis, or IPF, saying the seven-day study met its objective of demonstrating short-term safety and tolerability.
We also report on an experimental diagnostic approach that can detect tuberculosis exposure and infection at an earlier stage than current methods.
MNKD Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety & Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that the Company will report second quarter 2026 financial results after market close on Wednesday, August 5, 2026.
MannKind Corporation (NASDAQ: MNKD - Get Free Report)'s stock price gapped up prior to trading on Friday. The stock had previously closed at $3.89, but opened at $4.06. MannKind shares last traded at $3.9950, with a volume of 1,925,140 shares traded. Key Stories Impacting MannKind Here are the key news stories impacting MannKind this week:
Mannkind Corporation (NASDAQ:MNKD) shares are trading higher as the company recently announced the U.S. Food and Drug Administration's (FDA) approval of Furoscix ReadyFlow, an at-home treatment option for adults with heart failure or chronic kidney disease.